Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Scientists investigate sits at the center of this dementia and brain health question.
Yes, scientists are making significant progress in slowing cognitive decline, with multiple promising approaches showing measurable results. Recent research has moved beyond hoping to delay mental deterioration toward actually achieving it—some treatments slow cognitive decline by around 30%, brain stimulation techniques have demonstrated 44% effectiveness in slowing decline, and specific lifestyle interventions have proven they can reduce dementia risk by nearly half. The convergence of breakthrough discoveries in protein mechanisms, FDA-approved drug treatments, innovative brain stimulation therapies, and blood-based diagnostic tests means that cognitive decline is becoming increasingly preventable and treatable, rather than an inevitable part of aging.
For example, the FDA-approved drug Leqembi now offers people with early-stage Alzheimer’s disease measurable cognitive benefits through regular IV infusions that clear brain plaque over 12 to 18 months. At the same time, researchers at Stanford University demonstrated that activating the vagus nerve with a specific molecule restored cognitive performance in aging mice to levels comparable to young animals. These aren’t theoretical possibilities—they represent concrete wins against cognitive decline that patients can access today.
Table of Contents
- What Mechanisms Are Scientists Targeting to Reverse Cognitive Decline?
- How Effective Are Current FDA-Approved Treatments for Slowing Cognitive Decline?
- How Is Early Detection Transforming the Ability to Treat Cognitive Decline?
- Can Brain Training and Non-Invasive Brain Stimulation Slow Decline?
- How Does the Gut-Brain Connection Influence Cognitive Decline?
- What Makes Some People’s Brains Stay Sharp Into Their 80s and 90s?
- What Modifiable Factors Can Actually Prevent or Delay Cognitive Decline?
- Conclusion
What Mechanisms Are Scientists Targeting to Reverse Cognitive Decline?
scientists have identified specific molecular culprits driving cognitive dysfunction in aging brains. A major breakthrough came with the discovery that the FTL1 protein plays a central role in cognitive decline. Researchers found that clearing this protein from the brain helped rebuild lost neural connections in the hippocampus—the region critical for memory—and actually reversed existing damage in animal models.
This discovery matters because it shifts the conversation from slowing decline to reversing it, suggesting the brain retains remarkable plasticity even in advanced age. The FTL1 research exemplifies how precision neuroscience works: identify the exact molecular problem, demonstrate that removing it restores function, then develop treatments to target that specific pathway. This targeted approach is fundamentally different from earlier dementia research that relied on broader interventions. When scientists can point to a specific protein and show its removal restores memory-related connections, they’re working with a biological mechanism they can actually manipulate and measure.
How Effective Are Current FDA-Approved Treatments for Slowing Cognitive Decline?
Two FDA-approved monoclonal antibody treatments—Leqembi (lecanemab) and Kisunla (donanemab)—have demonstrated that you can meaningfully slow cognitive decline in people with early-stage Alzheimer’s disease. Both treatments achieve approximately 30% slowing of cognitive decline, which means a person who would normally experience noticeable mental changes over two years might stretch that progression to nearly three years. These are not cures, and the benefit isn’t experienced as a sudden improvement, but rather as a pause in decline that extends functional independence.
How these treatments work is equally important: both clear the majority of beta-amyloid plaque deposits from the brain over the course of 12 to 18 months of IV infusion treatment. However, this comes with a significant limitation—they require regular hospital or clinic visits for infusions, and some patients experience amyloid-related imaging abnormalities (ARIA), which are brain changes that require careful monitoring. Additionally, these treatments only work in people with early-stage disease and detectable amyloid pathology. By the time someone has progressed to moderate or severe dementia, these treatments are no longer effective, underscoring why early detection has become crucial.
How Is Early Detection Transforming the Ability to Treat Cognitive Decline?
Detection represents the bottleneck in treating cognitive decline early, which is where most treatments work best. In May 2025, the FDA approved the Lumipulse G plasma biomarker test—a blood test that can diagnose Alzheimer’s disease in people experiencing cognitive symptoms. This simple blood test measures phosphorylated tau 217 and beta-amyloid 1-42 ratios, meaning doctors no longer need PET scans or cognitive testing to identify whether someone’s memory problems are from Alzheimer’s pathology.
The practical impact is substantial: a person noticing memory lapses can now get a definitive answer from their primary care doctor with a routine blood draw, rather than waiting for specialist referrals and expensive imaging. This acceleration of diagnosis means treatments like Leqembi and Kisunla can be started when they’re most effective—in the earliest stages of disease, before significant brain damage has accumulated. However, one important caveat: a positive blood test indicates Alzheimer’s pathology is present, but not all people with this pathology will develop cognitive symptoms in their lifetime, so diagnosis still requires clinical judgment and symptom confirmation.
Can Brain Training and Non-Invasive Brain Stimulation Slow Decline?
Two distinct approaches—cognitive training and targeted brain stimulation—offer promising alternatives or complements to medication. Adults age 65 and older who completed just 5 to 6 weeks of cognitive speed training showed sustained protection against dementia diagnosis for up to 20 years afterward, including reduced rates of Alzheimer’s disease specifically. This long-term benefit from relatively brief training suggests that the brain’s learning systems, even in advanced age, can build protective resilience that extends decades into the future. More dramatically, Sinaptica Therapeutics’ personalized, non-invasive brain stimulation therapy showed 44% slowing of cognitive decline in a Phase 2 clinical trial of people with mild-to-moderate Alzheimer’s disease while simultaneously improving behavioral symptoms and maintaining daily functioning.
The comparison is striking: non-invasive brain stimulation achieved stronger decline slowing than the FDA-approved drug treatments. However, brain stimulation is not yet widely available—it remains experimental and restricted to clinical trial participants. Additionally, both cognitive training and brain stimulation require active engagement and patient compliance, unlike medications that work passively. For people with cognitive decline that affects motivation or attention, adherence can be challenging.
How Does the Gut-Brain Connection Influence Cognitive Decline?
A surprising discovery at Stanford Medicine revealed an unexpected pathway to restoring cognitive function: the gut-brain axis. Researchers found that when they treated aging mice with a molecule that activates the vagus nerve—the major communication highway between gut and brain—cognitive performance improved to levels indistinguishable from young animals. This wasn’t a modest improvement but a complete normalization of memory and processing speed. The mechanism suggests that aging disrupts signals traveling between the gut and brain, and restoring this communication can reverse cognitive decline.
This opens entirely new therapeutic avenues, since targeting vagal signaling might be simpler than clearing brain plaques or stimulating brain tissue directly. However, this research remains in the preclinical stage—it worked in mice, and human trials are still in development. The translation from animal models to human treatments typically takes years, and what works in controlled laboratory settings doesn’t always replicate in the complexity of the human body. This is why such research is considered exploratory rather than a currently available option for patients.
What Makes Some People’s Brains Stay Sharp Into Their 80s and 90s?
Researchers studying “SuperAgers”—people with exceptionally sharp minds in their 80s and 90s—have identified a striking biological signature: these individuals produce 2 times as many young neurons as cognitively healthy adults and 2.5 times as many as people with Alzheimer’s disease. Neurogenesis, the brain’s ability to generate new neurons, is directly correlated with cognitive preservation. SuperAgers demonstrate that the aging brain retains the capacity to produce new brain cells throughout life, and that this neurogenesis rate appears to be the difference between normal aging and exceptional cognitive preservation.
Understanding SuperAgers provides a roadmap for prevention: if continuous neurogenesis protects cognitive function, then interventions that stimulate neuron production—whether through physical exercise, cognitive challenge, social engagement, or specific molecular targets—might enable more people to age cognitively as well as SuperAgers do. This research suggests cognitive decline is not an inevitable consequence of aging, but rather a consequence of brain biology failing to maintain itself. The implication is hopeful: maintaining the conditions that favor neurogenesis might be one of the most powerful preventive measures available.
What Modifiable Factors Can Actually Prevent or Delay Cognitive Decline?
The Lancet Commission synthesized decades of dementia research and identified 14 modifiable risk factors for dementia, concluding that addressing these factors could prevent or delay up to 45% of dementia cases worldwide. These aren’t hypothetical risk factors—they’re specific, changeable aspects of life: cognitive and social engagement, physical activity, healthy diet, sleep quality, cardiovascular health, hearing correction, and others. The power of this finding is that nearly half of dementia cases might be preventable through lifestyle changes alone.
The US POINTER Study demonstrated these interventions in action, showing that when older adults at risk for cognitive decline received coordinated interventions including physical exercise, improved nutrition, cognitive engagement, social participation, and metabolic monitoring, they experienced significant measurable improvements in cognitive function. This wasn’t a single intervention but a comprehensive approach—the combination was more effective than any single element. However, one practical limitation is that these comprehensive programs require sustained engagement over months and years, consistent effort from participants, and often access to resources not universally available. The lifestyle factors that prevent dementia are well-understood; the challenge is maintaining them as habits rather than temporary efforts.
Conclusion
Scientists have moved decisively beyond investigating whether cognitive decline can be slowed to demonstrating multiple proven methods that achieve it. The evidence spans from molecular biology (FTL1 protein clearing), to FDA-approved medications (Leqembi, Kisunla achieving 30% slowing), to behavioral interventions (cognitive training showing 20-year protective effects), to novel approaches like vagal activation and brain stimulation.
Each approach provides different benefits, carries different limitations, and works best in different stages of cognitive decline, meaning that slowing cognitive decline is increasingly a matter of matching the right intervention to the right person at the right time. The next steps for anyone concerned about cognitive health are clear: get early detection through blood biomarker testing if cognitive changes appear; discuss available treatments with a neurologist if diagnosis is confirmed; adopt the modifiable lifestyle factors that prevent decline in the first place; and engage in cognitive and social activities that appear to maintain brain vitality even in advanced age. Cognitive decline is no longer an inevitable part of aging—it’s becoming a treatable medical condition with multiple evidence-based options for prevention, early intervention, and slowing progression.
You Might Also Like
- Scientists Link Cellular Changes to Cognitive Decline
- New Alzheimer’s Treatment Reverses Cognitive Decline in Early Testing
- Experts Identify New Patterns Linked to Cognitive Decline
For more, see Alzheimer’s Association — caregiving.
